Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Castle Biosciences Inc (NQ: CSTL )

29.81 +0.93 (+3.22%)
Streaming Delayed Price Updated: 2:46 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Castle Biosciences Inc

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
51 Biggest Movers From Yesterday
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares surged 148.2% to close at $5.61 on Tuesday after the company announced that two of its designed mRNA molecules are... 
Via Benzinga
Castle Biosciences to Present at the 21st Annual Needham Virtual Healthcare Conference
From Castle Biosciences, Inc.
Via Business Wire
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... 
Via Benzinga
Castle Biosciences Adds Mental Health Testing Solutions Via AltheaDx Acquisition
Castle Biosciences Inc (NASDAQ: CSTL) has agreed to acquire AltheaDx Inc, a commercial-stage molecular diagnostics company,  
Via Benzinga
Castle Biosciences to Acquire AltheaDx
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Receives Advanced Diagnostic Laboratory Test (ADLT) Status for TissueCypher® Barrett’s Esophagus Test from the Centers for Medicare & Medicaid Services (CMS)
From Castle Biosciences, Inc.
Via Business Wire
Data to be Presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting Demonstrate Ability of DecisionDx®-Melanoma and DecisionDx®-SCC to Inform Clinical Decision Making
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences: Q4 Earnings Insights
Castle Biosciences (NASDAQ:CSTL) reported its Q4 earnings results on Monday, February 28, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Introduction of Innovative PCR-Based Detection Methods Surges Fueled by Pandemic and Other Diseases
Palm Beach, FL – February 18, 2022 – FinancialNewsMedia.com News Commentary – PCR testing and the COVID-19 diagnostic testing market has, unexpectantly, been growing at a substantial rate the past few... 
Via FinancialNewsMedia
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Castle Biosciences to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on Monday, Feb. 28, 2022
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Collaborates with the National Cancer Institute to Link DecisionDx®-Melanoma Testing Data with SEER Registries’ Cutaneous Melanoma Cases
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Named a Winner of the 2022 Top Workplaces USA Award
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences to Present Data at Maui Derm for Dermatologists 2022
From Castle Biosciences, Inc.
Via Business Wire
Recently Published Data Confirm DecisionDx®-SCC as a Significant and Independent Risk-Stratification Tool in Patients with Squamous Cell Carcinoma and One or More Risk Factors
From Castle Biosciences, Inc.
Via Business Wire
Data Published in Ocular Oncology and Pathology Demonstrates Highly Accurate Performance of DecisionDx®-UMSeq for Patients with Uveal Melanoma
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2021 Results
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences to Present at the 24th Annual Needham Growth Conference
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Completes Acquisition of Cernostics
From Castle Biosciences, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 7, 2022
Upgrades According to Wolfe Research, the prior rating for CVR Energy Inc (NYSE: 
Via Benzinga
Castle Biosciences Presents Data Reinforcing the Clinical Utility of Its DecisionDx® Dermatologic Portfolio
From Castle Biosciences, Inc.
Via Business Wire
Data Demonstrating DecisionDx®-Melanoma Was a Significant, Independent Predictor of Metastatic Recurrence in Stage I-III Cutaneous Melanoma Published in Future Oncology
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Named in Inc.’s First-Annual Best-Led Companies
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Named a 2021 Houston Chronicle Top Workplace
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Announces Third Quarter 2021 Results
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Releases Inaugural Environmental, Social and Governance (ESG) Report
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Publishes DecisionDx®-Melanoma Study on the Validation of the i31-GEP SLNB Artificial Intelligence Algorithm
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences’ Full DecisionDx® Portfolio of Dermatologic Tests to Be Interfaced with EMA® Electronic Health Records System
From Castle Biosciences, Inc.
Via Business Wire
DecisionDx®-Melanoma Integrated Test Result Now Includes i31-GEP for Risk of Recurrence
From Castle Biosciences, Inc.
Via Business Wire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.